Gst-hg131: a new hepatitis B drug developed by guangshengtang and Wuxi apptec

Guangshengtang announced in the evening of February 28 that recently, the company and Wuxi apptec signed a "cooperative development contract" for "research and development of new hepatitis B drug gs-hg131" According to the contract, both parties shall complete the research work related to preclinical candidate drugs (PCC) and preclinical compounds (ind) of gst-hg131 project, so as to ensure the smooth application of clinical trial approval documents The total R & D cost of the project is 32 million yuan only, and the company undertakes 24 million yuan only, which shall be paid to Wuxi apptec in installments according to the contract The project is at the leading level in the world and has international competitiveness The candidate compounds have an innovative therapeutic mechanism different from the existing hepatitis B drugs, that is, inhibiting the secretion of HBsAg The new drugs can effectively inhibit the expression of HBsAg, avoid the depletion of T cell function caused by a large number of exposure to HBsAg, and restore the immune system function Combined with the existing nucleoside direct antiviral drugs, they can effectively inhibit the replication of HBV virus and play a good synergistic effect Guangshengtang said that the signing of this cooperation and development contract is the specific implementation of the strategic cooperation ideas and ideas between the company and Wuxi apptec, and the further promotion and implementation of the implementation of the strategic cooperation between the two sides At the same time, the implementation of the project will enrich the company's R & D reserves of class I new drugs, lay a solid foundation for the company's innovation and development, practice guangshengtang, the enterprise dream of seeking scientific solutions for human liver health, further improve the company's overall strength and market competitive advantage, improve the company's future profitability, and meet the interests of all shareholders and the company's development strategy.